Contrave vs Semaglutide: Comparing Two Weight Loss Medications

Contrave® and semaglutide (available as Wegovy® for weight management) represent two fundamentally different approaches to prescription weight loss. While both are FDA-approved for chronic weight management, they work through different mechanisms, have different side effect profiles, and may suit different patient populations. This guide compares these two medications to help you understand the key differences.

What Is Contrave?

Contrave is an oral medication that combines two active ingredients:

• Naltrexone (8 mg per tablet): Originally used to treat opioid and alcohol dependence, naltrexone is an opioid antagonist that may help reduce food cravings and the rewarding aspects of eating.
• Bupropion (90 mg per tablet): An antidepressant (also marketed as Wellbutrin®) that acts on dopamine and norepinephrine pathways. It may help reduce appetite and increase energy expenditure.

The combination targets the brain's reward and appetite centers, working primarily on the hypothalamus and mesolimbic dopamine system. Contrave is taken orally, with the maintenance dose being two tablets twice daily (four tablets total per day).

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist that mimics the naturally occurring GLP-1 hormone. For weight management, it is FDA-approved as Wegovy® at the 2.4 mg weekly dose. It works by:

• Activating appetite-regulating centers in the brain to reduce hunger
• Slowing gastric emptying so you feel full longer
• Improving insulin sensitivity and blood sugar regulation

Semaglutide is administered as a once-weekly subcutaneous injection with a gradual dose escalation over 16–20 weeks.

Effectiveness Comparison

The weight loss outcomes for these two medications differ meaningfully based on clinical trial data:

Contrave Clinical Data

The COR (Contrave Obesity Research) clinical trial program found that participants taking Contrave lost an average of approximately 5–8% of their body weight over 56 weeks. The COR-I trial reported that approximately 42% of Contrave users achieved at least 5% weight loss, compared to approximately 17% of placebo users.

Semaglutide Clinical Data

The STEP clinical trial program reported more substantial average weight loss. In STEP 1, participants taking semaglutide 2.4 mg lost an average of approximately 15% of body weight over 68 weeks. Approximately 86% achieved at least 5% weight loss, and approximately one-third achieved at least 20% weight loss.

Important context: Direct head-to-head trials between Contrave and semaglutide have not been published, and clinical trial populations may differ. Individual results with either medication vary significantly.

Side Effect Profiles

Contrave Common Side Effects

• Nausea (the most common, usually improving over time)
• Constipation
• Headache
• Vomiting
• Dizziness
• Insomnia
• Dry mouth

Serious concerns: Contrave carries a boxed warning about suicidal thoughts and behaviors associated with bupropion. It is contraindicated in patients with seizure disorders, eating disorders (bulimia or anorexia nervosa), those undergoing abrupt discontinuation of alcohol or sedatives, and those taking opioid medications or MAO inhibitors. It may also increase blood pressure and heart rate.

Semaglutide Common Side Effects

• Nausea (the most common, usually improving with dose escalation)
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Headache
• Fatigue

Serious concerns: Semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of MTC or MEN 2. Other serious but rare risks include pancreatitis, gallbladder disease, and acute kidney injury.

Administration and Convenience

• Contrave: Oral tablets taken twice daily (up to 4 tablets/day at maintenance). No injections required. Dose escalation over 4 weeks.
• Semaglutide (Wegovy): Once-weekly subcutaneous injection using a pre-filled pen. Dose escalation over 16–20 weeks. Requires refrigeration.

For patients who prefer oral medications and want to avoid injections, Contrave may be more appealing. For those who prefer a once-weekly dosing schedule, semaglutide may be more convenient.

Cost Considerations

Both medications can be expensive without insurance coverage. Costs vary based on insurance plans, pharmacy, and available manufacturer programs. Generally:

• Contrave tends to be less expensive than semaglutide at retail pricing, with generic versions potentially becoming available.
• Semaglutide (Wegovy) is typically priced at a premium as a newer biologic medication. Insurance coverage varies widely.

Both manufacturers offer savings programs for eligible patients. Check current pricing and coverage options with your provider and insurance plan.

Who Might Be a Better Candidate for Each?

Contrave May Be More Appropriate For:

• Patients who prefer oral medication over injections
• Those with significant food cravings or emotional eating patterns
• Patients who also have depression (bupropion has antidepressant effects)
• Those for whom cost is a primary concern
• Patients who cannot take GLP-1 medications due to contraindications

Semaglutide May Be More Appropriate For:

• Patients seeking more significant weight loss based on clinical trial data
• Those who prefer once-weekly dosing
• Patients with type 2 diabetes or prediabetes (semaglutide has metabolic benefits)
• Those with cardiovascular risk factors (the SELECT trial showed cardiovascular benefits)
• Patients who cannot take Contrave due to seizure history or other contraindications

Can You Take Both?

Combining Contrave and semaglutide is not a standard practice and has not been studied in clinical trials. Combining weight loss medications should only be considered under direct medical supervision, as the risks of combination therapy are not well-characterized.

The Bottom Line

Contrave and semaglutide are both FDA-approved for weight management but differ significantly in their mechanisms, effectiveness, side effect profiles, and administration. Semaglutide has demonstrated greater average weight loss in clinical trials, while Contrave offers an oral alternative that may suit patients who prefer not to inject or who have specific mental health considerations. The right choice depends on your individual health profile, preferences, and goals — a decision best made with a licensed provider.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.